Main Competitive Advantages :Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Reputation,Quality Service
Business Type :Manufacturer
R&D Capacity :Own Brand
Main Sales Markets :North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Product Range :Bormioli Pharma portfolio is organized into three product segments, specifically tailored to meet the needs of the treatments they will support:
forTherapy: high-value, accurate packaging systems ideal for prescription drugs:
• Injection Containers (Moulded and Tubular Glass Type I; PEN; COC)
• Infusion Bottles
• Rubber Stoppers and Aluminum Gear
• Vertical Dropper Systems
forHealth: easy-to-use, safe packaging solutions designed for over-the -counter medicines:
• High-quality CRC Caps, Tamper evident plastic caps
• Glass and Plastic (PET; PP; HDPE; LDPE) Oral Bottles and Jars
• Ophthalmic Containers with calibrated nozzles & caps
• Dropper Pipette Systems
forLife: attractive, clever packaging kits conceived for wellbeing products:
• Patented Dual Chamber Systems enhanced with high moisture barriers
• Pills Jars and Oral Liquid Bottles
• Cosmetic Systems and Containers
• Sustainable Container Ranges (from recycled or renewable raw sources)
a reliable, innovative and sustainable partner for the pharma industry.
Bormioli Pharma is an international leader in the production of pharma containers in glass and plastics, with over 100 years of expertise.
With a global presence in over 100 countries, the company counts more than 1,300 employees and 10 plants in Europe, specialized in the manufacturing of glass and plastic packaging for pharmaceutical, generics and biotech companies and CMOs.
It is fully owned by the investment firm Triton, a pan-European investment fund, which invests in medium-sized companies all over Europe.
Since the company has been acquired by Triton, in 2017, Bormioli Pharma has continued to grow and expand, always keeping an eye on innovation and sustainability.
Even more robust, reliable and global.
In the last three years, Bormioli Pharma has undertaken a consolidation process, through both investments in the existing plants and M&As in Continental Europe.
As a result of this process, the company enhanced its production platform both for molded and tubing glass, also producing in-house accessories such as closures, rubber stoppers and dropper pipettes, becoming the one-stop solution for the pharmaceutical industry.
Moreover, the company has become a truly global one, thanks to the opening of commercial offices overseas in USA and in China, where Bormioli Pharma is present with a sales branch in Shanghai.
Innovating to make the difference.
A couple of years ago, the company launched Bormioli Pharma Invents, a program based on an Open Innovation approach.
This model relies on some of the main drivers of change in the pharmaceutical primary packaging market - usability, connectivity, traceability and sustainability - and aims at proposing to the market innovative packaging prototypes and concepts.
Sustainability as a deep committment towards industry, people and planet.
Bormioli Pharma has always been at the forefront of sustainable pharma packaging and is now able to offer up to ten different low-impact product routes, from recycled plastics, up to bioplastics and recycled glass.
But the committment of the company goes beyond the product offer. Bormioli Pharma has announced an ambitious goal to be the industry catalyst towards more responsible solutions: using 50% sustainable raw materials, such as recycled plastic, bioplastics and glass from recycled sources, while manufacturing its products by 2025.
All the actions, plans and strategies of the company are carried out always keeping in mind a single purpose: